Lexicon Pharmaceuticals, Inc.

General ticker "LXRX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $380.8M (TTM average)

Lexicon Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -10.3%.

Estimated limits based on current volatility of 5.9%: low 0.67$, high 0.75$

Factors to consider:

  • Earnings expected soon, date: 2025-05-01 bmo
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [0.48$, 1.58$]
  • 2025-12-31 to 2026-12-31 estimated range: [0.56$, 1.67$]

Financial Metrics affecting the LXRX estimates:

  • Negative: Non-GAAP EPS, $ of -0.64 <= 0.04
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -42.36 <= 1.79
  • Negative: negative Net income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: 43.26 < Shareholder equity ratio, % of 48.91 <= 63.75
  • Negative: Industry earnings per price (median), % of -27.42 <= 0
  • Positive: Inventory ratio change, % of -23.30 <= -1.01

Similar symbols

Short-term LXRX quotes

2025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-250.30.40.50.60.70.8
Price $

Long-term LXRX plot with estimates

0.511.522.533.5Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.2−0.15−0.1−0.050
LXRXS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.14MM $1.20MM $31.08MM
Operating Expenses $100.90MM $172.95MM $228.20MM
Operating Income $-100.76MM $-171.75MM $-197.12MM
Non-Operating Income $-1.18MM $-5.37MM $-3.29MM
R&D Expense $52.82MM $58.89MM $84.48MM
Income(Loss) $-101.94MM $-177.12MM $-200.40MM
Profit(Loss)* $-103.13MM $-177.12MM $-200.40MM
Stockholders Equity $117.12MM $93.11MM $145.95MM
Inventory $0.00MM $0.38MM $0.23MM
Assets $194.30MM $229.43MM $298.42MM
Operating Cash Flow $-88.85MM $-161.90MM $-178.78MM
Capital expenditure $1.33MM $0.47MM $1.03MM
Investing Cash Flow $-71.08MM $-49.94MM $-15.38MM
Financing Cash Flow $142.21MM $187.96MM $238.35MM
Earnings Per Share** $-0.62 $-0.80 $-0.63

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.